Fortress Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FBIO research report →
Range $5 – $5
Price Chart
About the company
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments.
- CEO
- Lindsay A. Rosenwald
- IPO
- 2011
- Employees
- 78
- HQ
- Bay Harbor Islands, FL, US
Get TickerSpark's AI analysis on FBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $63.37M
- P/E
- 0.65
- Fwd P/E
- 0.73
- PEG
- 0.00
- P/S
- 0.91
- P/B
- 0.40
- EV/EBITDA
- -0.35
- Div Yield
- 0.00%
- Gross Margin
- 63.17%
- Op Margin
- -42.47%
- Net Margin
- 143.05%
- ROE
- 74.69%
- ROIC
- -13.12%
Latest fiscal year · YoY change
- Revenue
- $63.26M+9.7%
- Gross Profit
- $42.34M+15.1%
- Op Income
- $-70,221,000
- Net Income
- $6.82M+114.8%
- EPS
- $-0.07+97.5%
- OCF Growth
- +18.0%
- FCF Growth
- +30.9%
- 52W High
- $4.53
- 52W Low
- $1.64
- 50D MA
- $2.07
- 200D MA
- $2.69
- Beta
- 1.25
- RSI (14)
- 50
- Avg Volume
- 273.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Journey Medical said Q3 2026 showed faster revenue growth than spending, with Emrosi continuing to gain traction and the company turning positive on EBITDA for a second straight quarter.· November 12, 2026
- Total revenue rose 8% year over year to $19 million, driven by Emrosi, which generated $9 million in net revenue.
- Emrosi prescriptions reached approximately 40,000, up from about 36,000 in Q2, and unique prescribers grew to over 5,000.
- Gross margin improved to 69% from 67%, and GAAP net loss narrowed to $1.3 million, or $0.05 per share, from $3.9 million, or $0.14 per share.
- The company said it had positive EBITDA and adjusted EBITDA for the quarter, marking a second consecutive quarter of positive EBITDA.
- Management highlighted a large national formulary win expected to take effect in early 2027 and said 40% of commercial lives currently have high-quality access.
Total revenue was $19 million in Q3 2026 versus $15 million in Q3 2025, an 8% increase year over year. Emrosi net revenue was $9 million, up year over year and sequentially, while total Emrosi prescriptions were approximately 40,000 versus about 36,000 in Q2, about 8% sequential growth. Gross margin was 69% compared with 67% a year ago. SG&A was $12.6 million versus $12.1 million, with a $1.7 million one-time vendor dispute settlement included in the quarter. GAAP net loss was $1.3 million, or $0.05 per share, versus a net loss of $3.9 million, or $0.14 per share, in Q3 2025. The company said EBITDA and adjusted EBITDA were positive. Cash ended at $22.3 million versus $24.1 million at December 31, 2025. For guidance, management did not give formal 2027 revenue or EBITDA guidance, but said it expects ASP and revenue growth to improve as a large national plan covering over 25 million lives begins in Q1 2027 and additional formulary wins come online.
Claude Maraoui emphasized that Emrosi is building momentum through rising prescriptions, expanding prescriber count, improving payer access, and strong refill demand. He said the company has already exceeded its internal goal of more than 5,000 unique prescribers and believes there is still significant room to grow given the size of the dermatology market. His tone was constructive and confident, but he also said the company is being thoughtful about spending and is considering whether to provide formal 2027 guidance later.
Joseph Benesch focused on the financial leverage in the model, noting revenue growth outpaced expense growth and that the company generated positive EBITDA again. He cited 69% gross margin, $12.6 million in SG&A, and the $1.7 million one-time cash settlement for a former vendor dispute that had been previously reserved. He also said cash was $22.3 million at quarter end and framed future spending as measured, with SG&A expected to remain consistent or slightly lower as a percentage of revenue even as the company adds some sales resources.
Analysts pressed on Emrosi net revenue per prescription, high-quality formulary coverage, and the likely impact of a large national plan expected in Q1 2027. Management said the plan covers over 25 million lives, should improve ASP and gross-to-net over time, and could accelerate the shift from uncovered to reimbursed prescriptions, though deductible resets may delay the benefit somewhat early in the year. Questions also focused on the $1.7 million vendor settlement, which management said was a nonrecurring, fully resolved cash outlay, and on the October copay-bridging transition, which management said caused temporary volatility but is recovering.
The call showed clear momentum in Emrosi: prescriptions, prescribers, refill rates, and payer coverage all moved in the right direction. Management also pointed to a major upcoming formulary win, a growing commercial footprint, and the possibility of additional journal publications and guideline inclusion as catalysts for 2027.
Management acknowledged short-term volatility from copay program changes and said the benefit from new payer coverage may take time to flow through because of deductible resets and patient mix. They also did not provide formal 2027 guidance and said they may remain cautious about doing so in the first half of next year, while SG&A will still rise as they invest in the brand and market access.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 69.1%
- Shares Outstanding
- 33.35M
- Float Shares
- 23.04M
of shares held by institutions
60 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Millennium Management LLC | 2.17M | ▲ 2.17M |
| Vanguard Group Inc | 1.10M | ▲ 150.24K |
| Vanguard Capital Management LLC | 1.04M | 0 |
| Opaleye Management Inc. | 720.00K | ▼ 170.00K |
| Mackenzie Financial Corp | 528.91K | ▼ 26.76K |
| Acadian Asset Management LLC | 459.02K | ▲ 351.71K |
| Geode Capital Management, LLC | 285.18K | ▼ 15.34K |
| Bridgeway Capital Management, LLC | 227.37K | ▲ 50.00K |
| Panagora Asset Management Inc | 226.59K | ▲ 160.57K |
| Blackrock, Inc. | 220.71K | ▼ 4.07K |
| Marshall Wace, Llp | 215.82K | ▲ 215.82K |
| Citadel Advisors LLC | 169.11K | ▲ 92.04K |
Held by 27 ETFs
Biggest fund positions in FBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 26 | ROSENWALD LINDSAY A MD | buy | 17,456 |
| Nov 18, 26 | ROSENWALD LINDSAY A MD | buy | 54,776 |
| Nov 17, 26 | ROSENWALD LINDSAY A MD | buy | 64,491 |
| Nov 19, 26 | Jin David | buy | 7,605 |
| Nov 18, 26 | Jin David | buy | 25,000 |
| Nov 17, 26 | Jin David | buy | 15,000 |
| Oct 1, 26 | Jin David | other | 1,190 |
| Jun 22, 26 | Jin David | other | 400,000 |
| Apr 1, 26 | Jin David | other | 2,967 |
| Mar 18, 26 | ROSENWALD LINDSAY A MD | other | 475,424 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FBIO coverage
Recent articles, reports, and earnings notes.
No research on FBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FBIO report →Fortress Biotech: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 13
Fortress Biotech Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 13
Fortress Biotech, Inc. (FBIO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Fortress Biotech Q3 Earnings Call Highlights
marketbeat.com · Nov 12
Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
globenewswire.com · Nov 12
Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)
globenewswire.com · Nov 10
Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
globenewswire.com · Nov 5
Johnson & Johnson (NYSE:JNJ) vs. Fortress Biotech (NASDAQ:FBIO) Head to Head Review
defenseworld.net · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.